89
Participants
Start Date
April 29, 2015
Primary Completion Date
February 6, 2019
Study Completion Date
February 6, 2019
CMB305
A combination of LV305 administered intradermally (ID) and G305 administered intramuscularly (IM)
atezolizumab
IV Infusion
Mayo Clinic Rochester, Rochester
Monter Cancer Research, Lake Success
Fox Chase cancer Center, Philadelphia
MedStar Washington Hospital Center, Washington D.C.
Duke Cancer Institute, Durham
Levine Cancer Institute, Charlotte
Georgia Cancer Specialists, Sandy Springs
Mayo Clinic of Jacksonville, Jacksonville
Vanderbilt University, Nashville
University of Iowa Hospital and Clinics, Iowa City
Northwestern University Feinburg School of Medicine, Chicago
Washington University in St. Louis, St Louis
University of Colorado Cancer Center, Aurora
Sarcoma Oncology Research Center, Santa Monica
Stanford University Medical Center, Palo Alto
Scca/Fhcrc, Seattle
Massachusetts General Hospital, Boston
University of Vermont Cancer Center, Burlington
Collaborators (1)
Genentech, Inc.
INDUSTRY
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY